Metabolic activation of toxins: Tissue-specific expression and metabolism in target organs

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 767-774

  Pelkonen, Olavi ^a   Raunio, Hannu ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

CYP; Cytochrome P450; Metabolic activation; Polymorphism; Tissue specific expression; Xenobiotic metabolism

Indexed keywords

AFLATOXIN B1; CYTOCHROME P450; DEBRISOQUINE; PARACETAMOL; TOXIN;

CELL TYPE; CONFERENCE PAPER; HUMAN; HYDROXYLATION; LIVER; LIVER CANCER; LIVER TOXICITY; METABOLIC ACTIVATION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET ORGAN; TOXICITY;

EID: 0030868092     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4767     Document Type: Conference Paper

References (67)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42 (1996).
2. Cohen GM, Moss EJ. Tissue distribution of drug metabolizing enzymes in relation to toxicity. In: Drug Metabolism - from Molecules to Man (Benford DJ, Bridges JW, Gibson GG, eds). London:Taylor & Francis, 1978;90-707.
3. Pelkonen O, Neben DW. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol Rev 34:189-222 (1982).
4. Harris CC. Human tissues and cells in carcinogenesis research. Cancer Res 47:1-10 (1987).
5. Autrup H. Carcinogen metabolism in cultured human tissues and cells. Carcinogenesis 11:707-712 (1990).
6. Guengerich FP. Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 21:1-6 (1993).
7. Law MR. Genetic predisposition to cancer. Br J Cancer 61:195-206 (1990).
8. Idle JR. Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 247:259-266 (1991).
9. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol 14:77-87 (1993).
10. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility. Gene 159:113-121 (1995).
11. Pineau T, Fernandez-Salguero P, Lee SST, McPhail T, Ward JM, Gonzalez FJ. Neonatal lethality associated with respiratory distress in mice lacking cytochrome P450 IA2. Proc Natl Acad Sci USA 92:5134-5138 (1995).
12. Gonzalez FJ, Fernandez-Salguero P, Lee SST, Pineau T, Ward JM. Xenobiotic receptor knockout mice. Toxicol Lett 82/83:117-121 (1995).
13. Testa B, Jenner P. Inhibitors of cytochrome P450s and their mechanism of action. Drug Metab Rev 12:1-118 (1981).
14. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 23:123-146 (1992).
15. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 14:292-294 (1993).
16. Pelkonen O, Breimer DD. Role of environmental factors in the pharmacokinetics of drugs - considerations with respect to animal models. In: Handbook of Experimental Pharmacology (Welling PG, Balant LP, eds). Basel:Karger, 1994;289-332.
17. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407 (1991).
18. Pelkonen O, Rautio A, Raunio H. Specificity and applicability of probes for drug metabolizing enzymes. In: European Cooperation in the Field of Scientific and Technical Research - COST B1 Conference on the Variability and Specificity in Drug Metabolism (Alvan G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Paintaud G, Pithan K, eds). Luxembourg:European Commission, 1995;147-158.
19. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53:503-514 (1993).
20. Guengerich FP. Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 29:241-264 (1989).
21. Ryan DE, Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153-239 (1990).
22. Gelboin HV. Cytochrome P-450 and monoclonal antibodies. Biochem Pharmacol 45:413-453 (1993).
23. Murray BP, Edwards RJ, Murray S, Singleton AM, Davies DS, Boobis AR. Human hepatic CYP1A1 and CYP1A2 content, determined with specific anti-peptide antibodies, correlates with the mutagenic acivation of PhIP. Carcinogenesis 14:585-592 (1993).
24. Edwards RJ, Singleton AM, Murray BP, Davies DS, Boobis AR. Short synthetic peptides exloited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes. Biochem Pharmacol 49:39-47 (1995).
25. Murray GI, Burke MD. Immunohistochemistry of drug-metabolizing enzymes. Biochem Pharmacol 50:895-903 (1995).
26. Baron J, Voigt JM. Localization, distribution, and induction xenobiotic-metabolizing enzymes and aryl hydrocarbon hydroxylase activity within lung. Pharmacol Ther 47:419-4445 (1990).
27. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmacol Ther 45:1-38 (1990).
28. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 13:346-352 (1992).
29. McKinnon RA, Hall PM, Quattrochi LC, Tukey RH, McManus ME. Localization of CYP1A1 and CYP1A2 messenger RNA in normal human liver and in hepatocellular carcinoma by in situ hybridization. Hepatology 14:848-856 (1991).
30. Palmer CNA, Coates PJ, Davies SE, Shephard EA, Phillips IR. Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology 16:682-687 (1992).
31. Foley KP, Leonard MW, Engel JD. Quantitation of RNA using the polymerase chain reaction. Trends Genet 9:380-385 (1993).
32. Omiecinski CJ, Redlich CA, Costa P. Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues. Cancer Res 50:4315-4321 (1990).
33. Hakkola J, Pasanen M, Purkunen R, Saarikoski S, Pelkonen O, Mäenpää J, Rane A, Raunio H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. Biochem Pharmacol 48:59-64 (1994).
34. Raunio H, Pasanen M, Mäenpää J, Hakkola J, Pelkonen O. Expression of extrahepatic cytochrome P450 in humans. In: Advances in Drug Metabolism in Man (Pacifici GM, Fracchia GN, eds). Luxembourg:European Commission, Office for Official Publications of the European Communities, 1995;234-287.
35. Vanden Heuvel JP, Clark GC, Thompson CL, McCoy Z, Miller CR, Lucier GW, Bell DA. CYP1A1 mRNA levels as a human exposure marker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 14:2003-2006 (1993).
36. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298 (1995).
37. Meyer UA, Skoda RC, Zanger UM. The general polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms. Pharmacol Ther 46:297-308 (1990).
38. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422 (1994).
39. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J, Evans WE, Idle JR et al. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660 (1995).
40. Caporaso N, Goldstein A. Cancer genes: single and susceptibility: exposing the difference. Pharmacogenetics 5:59-63 (1995).
41. Wolf CR, Smith CAD, Forman D. Metabolic polymorphisms in carcinogen metabolizing enzymes and cancer susceptibility. Br Med Bull 50:718-731 (1994).
42. IARC. Tobacco smoking. In: IARC Monographs on Evaluation of Carcinogenic Risk of Chemicals to Humans. Vol 38. Lyon:International Agency for Research on Cancer, 1990;83-139.
43. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, Eggleston JC, Boyd MR, Hines RN. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 83:1333-1339 (1990).
44. Anttila S, Hietanen E, Vainio H, Camus A-M, Gelboin HV, Park SS, Heikkilä L, Karjalainen A, Bartsch H. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int J Cancer 47:681-685 (1991).
45. Landers JP, Bunce NJ. The Ah receptor and the mechanism of dioxin toxicity. Biochem J 276:273-287 (1991).
46. Dolwick KM, Schmidt JV, Carver LA, Swanson HI, Bradfield CA. Cloning and expression of a human Ah receptor cDNA. Mol Pharmacol 44:911-917 (1993).
47. Gram TE. Pulmonary toxicity of 4-ipomeanol. Pharmacol Ther 43:291-297 (1989).
48. Czerwinski M, McLemore TL, Philpot RM, Nhamburo PT, Korzekwa K, Gelboin HV, Gonzalez FJ. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450. Cancer Res 51:4636-4638 (1991).
49. Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523-530 (1995).
50. Kivistö KT, Griese E-U, Fritz P, Linder A, Hakkola J, Raunio H, Beaune P, Kroemer HK. Expression of cytochrome P4503A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumors. Naunyn-Schmiedeberg Arch Pharmacol 353:207-212 (1996).
51. Thornton-Manning JR, Ruangyuttikarn W, Gonzalez FJ, Yost GS. Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s. Biochem Biophys Res Commun 181:100-107 (1991).
52. Mizuno Y, Mori H, Kondo T. Potential of neuroprotective therapy in Parkinson's disease. CNS Drugs 1:45-56 (1994).
53. Warner M, Gustaffson J-Å. Cytochrome P450 in the brain: neuroendocrine functions. Front Neuroendocrinol 16:224-236 (1995).
54. Ravindranath V, Bhamre S, Bhagwat SV, Anandatheerthavarada HK, Shankar SK, Tirumalai PS. Xenobiotic metabolism in brain. Toxicol Lett 82/83:633-638 (1995).
55. Ghersi-Egea J-F, Perrin R, Leininger-Muller B, Grassiot M-C, Jeandel C, Floquet J, Cuny G, Siest G, Minn A. Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain. Biochem Pharmacol 45:647-658 (1993).
56. Strobel HW, Kawashima H, Geng J, Sequeira D, Bergh A, Hodgson AV, Wang H, Shen S. Expression of multiple forms of brain cytocrome P450. Toxicol Lett 639-643 (1995).
57. Sim E, Stanley LA, Risch A, Thygesen P. Xenogenetics in multifactorial disease susceptibility. Trends Genet 11:509-512 (1995).
58. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434-439 (1992).
59. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology. J Clin Psychopharmacol 14:1-14 (1994).
60. Kellerman G, Shaw CR, Luyten-Kellerman M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N Engl J Med 289:934-937 (1973).
61. Holz O, Krause T, Rudiger HW. Differences in DNA adduct formation between monocytes and lymphocytes after in vivo incubation with benzo[a]pyrene. Carcinogenesis 12:2181-2183 (1991).
62. Rojas M, Camus A-M, Alexandrov K, Husgafvel-Pursiainen K, Anttila S, Vainio H, Bartsch H. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effects of smoking. Carcinogenesis 13:929-933 (1992).
63. Cosma GN, Toniolo P, Currie D, Pasternak BS, Garte SJ. Expression of CYP1A1 gene in peripheral lymphocytes as a marker of exposure in railroad workers. Cancer Epidemiol Biomarkers Prev 1:137-142 (1992).
64. Okano P, Miller HN, Robinson RC, Gelboin HV. Comparison of benzo[a]pyrene and (-)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene metabolism in human blood monocytes and lymphocytes. Cancer Res 39:3184-3193 (1979).
65. Pyykkö K, Tuimala R, Aalto L, Perkiö T. Is aryl hydrocarbon hydroxylase activity a new prognostic indicator for breast cancer? Br J Cancer 63:596-600 (1991).
66. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Arch Biochem Biophys 311:437-442 (1994).
67. Carriere V, Goasduff T, Ratanasavanh D, Morel F, Gautier JC, Guillouzo A, Beaune P, Berthou F. Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chem Res Toxicol 6:852-857 (1993).